Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 6/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169403 | 0.82 | SYK (0.44) | TYK2SYKCSF1RZAP70 | |
| SCHEMBL10169431 | 0.78 | MEN1 (0.52) | TYK2MEN1KMT2ASYKZAP70 | |
| SCHEMBL10169532 | 0.77 | JAK2 (0.49) | TYK2SYKCSF1R | |
| SCHEMBL10169371 | 0.73 | STAT6 (0.55) | SYKSTAT6 | |
| SCHEMBL10169338 | 0.72 | SYK (0.52) | EGFRSYKSTAT6 | |
| SCHEMBL10169433 | 0.72 | MEN1 (0.47) | TYK2MEN1KMT2ASYKCSF1R | |
| SCHEMBL14923853 | 0.71 | SYK (0.56) | EGFRMEN1KMT2ASYK | |
| SCHEMBL10169441 | 0.71 | STAT6 (0.51) | EGFRSYKSTAT6 | |
| SCHEMBL10169331 | 0.71 | BTK (0.57) | EGFRTYK2SYKCSF1R | |
| SCHEMBL14923898 | 0.70 | SYK (0.49) | EGFRTYK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | EGFR 2225/4885HRH3 1169/4885TYK2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.